Clinical Trial Update: CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating subcutaneous octanorm in primary immunodeficiency diseases has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• Octanorm

Snippet

Sponsor: Octapharma | Conditions: Primary Immunodeficiency | Phase 3 | Status: COMPLETED | Results posted: 2020-09-22